Korean J Gastroenterol.  2009 Jun;53(6):388-390. 10.4166/kjg.2009.53.6.388.

Molecular Imaging of Pancreatic Cancer in a Preclinical Animal Tumor Model Using Targeted Multifunctional Nanoparticles. Gastroenterology 2009;136:1514-1525

• Cho YS

• KMID: 1792758
• DOI: http://doi.org/10.4166/kjg.2009.53.6.388

Abstract

No abstract available.

Reference

1. Yang GY, Wagner TD, Fuss M, Thomas CR Jr. Multimodal-ity approaches for pancreatic cancer. CA Cancer J Clin. 2005; 55:352–367.

2. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004; 2:606–621.

3. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999; 131:247–255.

4. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008; 6:1301–1308.

5. Weissleder R. Molecular imaging in cancer. Science. 2006; 312:1168–1171.

6. Lee JH, Huh YM, Jun YW, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007; 13:95–99.

7. Li H, Soria C, Griscelli F, et al. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: re-spective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway. Hum Gene Ther. 2005; 16:1157–1167.

8. Chen Y, Zheng B, Robbins DH, et al. Accurate discrim-ination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer. 2007; 120:1511–1517.

9. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997; 75:388–395.

10. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999; 117:1464–1484.

11. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol. 2005; 23:4524–4531.

12. Sturm PD, Hruban RH, Ramsoekh TB, et al. The potential diagnostic use of Kras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol. 1998; 186:247–253.